The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2019 | Moving to the frontline: gilteritinib plus chemo for newly diagnosed AML
Alexander Perl
• 15 Jun 2019
Alexander Perl, MD, of the University of Pennsylvania, Philadelphia, PA, explains the updated results from the Phase I study (NCT02236013) of gilteritinib in combination with induction and consolidation therapy in newly diagnosed acute myeloid leukemia (AML). This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.
